Successful Reperfusion with Endovascular Therapy Has Beneficial Effects on Long-Term Outcome Beyond 90 Days.


Journal

Cerebrovascular diseases (Basel, Switzerland)
ISSN: 1421-9786
Titre abrégé: Cerebrovasc Dis
Pays: Switzerland
ID NLM: 9100851

Informations de publication

Date de publication:
2019
Historique:
received: 04 11 2018
accepted: 26 02 2019
pubmed: 10 4 2019
medline: 26 2 2020
entrez: 10 4 2019
Statut: ppublish

Résumé

Recent studies have demonstrated that endovascular reperfusion therapy improves clinical outcomes at 90 days after ischemic stroke. However, the effects on long-term outcomes are not well known. We hypothesized that successful reperfusion might be associated with long-term improvement beyond 90 days after endovascular therapy. To assess the long-term effects beyond 90 days, we analyzed the association of successful reperfusion with a temporal change in modified Rankin Scale (mRS) score from 90 days to 1 year after endovascular therapy. We retrospectively analyzed a database of consecutive patients with acute ischemic stroke who received endovascular therapy between April 2006 and March 2016 at 4 centers. We compared the incidences of improvement and deterioration in patients with successful reperfusion (i.e., modified thrombolysis in cerebral infarction score of 2b or 3) with those in patients with unsuccessful reperfusion. We defined improvement and deterioration as decrease and increase on the mRS score by 1 point or more from 90 days to 1 year after endovascular therapy respectively. A total of 268 patients were included in the current study. The rate of patients with improvement tended to be higher in patients with successful reperfusion than in patients with unsuccessful reperfusion (20% [34/167 patients] vs. 12% [12/101], p = 0.07). The rate of patients with deterioration was lower in patients with successful reperfusion than in patients with unsuccessful reperfusion (25% [42/167] vs. 42% [42/101], p < 0.01). After adjustment for confounders, successful reperfusion was associated with improvement (adjusted OR 2.65; 95% CI 1.23-5.73; p < 0.05) and deterioration (adjusted OR 0.33; 95% CI 0.18-0.62; p < 0.01), independent of the 90-day mRS score. Successful reperfusion has further beneficial legacy effects on long-term outcomes beyond 90 days after stroke.

Sections du résumé

BACKGROUND AND PURPOSE
Recent studies have demonstrated that endovascular reperfusion therapy improves clinical outcomes at 90 days after ischemic stroke. However, the effects on long-term outcomes are not well known. We hypothesized that successful reperfusion might be associated with long-term improvement beyond 90 days after endovascular therapy. To assess the long-term effects beyond 90 days, we analyzed the association of successful reperfusion with a temporal change in modified Rankin Scale (mRS) score from 90 days to 1 year after endovascular therapy.
METHODS
We retrospectively analyzed a database of consecutive patients with acute ischemic stroke who received endovascular therapy between April 2006 and March 2016 at 4 centers. We compared the incidences of improvement and deterioration in patients with successful reperfusion (i.e., modified thrombolysis in cerebral infarction score of 2b or 3) with those in patients with unsuccessful reperfusion. We defined improvement and deterioration as decrease and increase on the mRS score by 1 point or more from 90 days to 1 year after endovascular therapy respectively.
RESULTS
A total of 268 patients were included in the current study. The rate of patients with improvement tended to be higher in patients with successful reperfusion than in patients with unsuccessful reperfusion (20% [34/167 patients] vs. 12% [12/101], p = 0.07). The rate of patients with deterioration was lower in patients with successful reperfusion than in patients with unsuccessful reperfusion (25% [42/167] vs. 42% [42/101], p < 0.01). After adjustment for confounders, successful reperfusion was associated with improvement (adjusted OR 2.65; 95% CI 1.23-5.73; p < 0.05) and deterioration (adjusted OR 0.33; 95% CI 0.18-0.62; p < 0.01), independent of the 90-day mRS score.
CONCLUSIONS
Successful reperfusion has further beneficial legacy effects on long-term outcomes beyond 90 days after stroke.

Identifiants

pubmed: 30965319
pii: 000499190
doi: 10.1159/000499190
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-134

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Kenichi Todo (K)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan, ktodo@neurol.med.osaka-u.ac.jp.
Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan, ktodo@neurol.med.osaka-u.ac.jp.

Nobuyuki Sakai (N)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Hirotoshi Imamura (H)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Hiroshi Yamagami (H)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, Suita, Japan.

Hidemitsu Adachi (H)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Tomoyuki Kono (T)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Junya Kobayashi (J)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Vascular Neurology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan.

Shiro Yamamoto (S)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Division of Stroke Medicine, National Hospital Organization Osaka Medical Center, Osaka, Japan.

Takeshi Morimoto (T)

Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.

Shoichi Tani (S)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Michi Kawamoto (M)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Manabu Sakaguchi (M)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasushi Ueno (Y)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Shinko Memorial Hospital, Kobe, Japan.

Takeharu Kunieda (T)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Ehime University School of Medicine, Matsuyama, Japan.

Osamu Narumi (O)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Amagasaki General Medical Center, Amagasaki, Japan.

Chiaki Sakai (C)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Akira Ishii (A)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Taku Hoshi (T)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurology, Osaka General Medical Center, Osaka, Japan.

Masaomi Koyanagi (M)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Amagasaki General Medical Center, Amagasaki, Japan.

Yohei Mineharu (Y)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Tatsuya Ishikawa (T)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

Yoji Kuramoto (Y)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan.

Shinsuke Sato (S)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery and Neurovascular Therapy, St. Luke's International Hospital, Tokyo, Japan.

Nobuyuki Ohara (N)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Vascular Neurology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan.

Koichi Arimura (K)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Neurosurgery, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Hajime Nakamura (H)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Takeo Nishida (T)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasufumi Gon (Y)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Toshiyuki Fujinaka (T)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Neurosurgery, National Hospital Organization Osaka Medical Center, Osaka, Japan.

Kazuhisa Yoshiya (K)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Haruhiko Kishima (H)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Hideki Mochizuki (H)

Stroke Center, Osaka University Graduate School of Medicine, Osaka, Japan.

Nobuo Kohara (N)

Comprehensive Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH